Fig. 7

JS-K inhibits tumor growth in vivo and JS-K and Cisplatin cooperate to enhance Cisplatin sensitivity of ovarian cancer A2780 and SKOV3 cells. (a) a-b. The effect of JS-K on body weight and tumor sizes in nude mice between the Cisplatin, JS-K and control groups were compared (n = 10, Mean ± SD); c-d. AST and ALT were detected by ELISA; e. Cisplatin, JS-K and control groups tumor were taken picture; f. HE staining and Immunohistochemistry analyzed of PCNA and P62 protein expression of tumor tissue of control group, JS-K group and Cisplatin group (400 × magnification). (b) Cell viability was analyzed by MTT method. (c) Cell apoptosis were detected by microscope and flow cytometry (Mean ± SD, 48 h treatment),—represents 40 μm